AKESF (AKESF) Stock Price & Analysis
AKESF (AKESF) rose 0.00% to USD 12 as of June 9, 2026 at 23:56 UTC, according to Nexqual real-time market data.
AKESF last closed at USD 12; the session ranged USD 11.94–12.2 on volume of 500 shares. Market capitalization is $11.05B, with a 52-week range of USD 11.05–23.15 (PNK). Source: Nexqual, June 9, 2026 at 23:56 UTC.
Key Statistics (as of June 9, 2026 at 23:56 UTC)
| Price | USD 12 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 12 |
| Open | USD 12.2 |
| Day Range | USD 11.94 – 12.2 |
| 52-Week Range | USD 11.05 – 23.15 |
| Volume | 500 shares |
| Market Cap | $11.05B |
| Exchange | PNK |
Technical Analysis (AKESF)
Nexqual's technical model rates AKESF "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:56 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.03 (oversold) |
| vs SMA50 | Below (USD 16.34) |
| MACD | -1.06 (negative) |
Analyst Ratings (AKESF)
Wall Street analysts rate AKESF "None", per Nexqual as of June 9, 2026 at 23:56 UTC.
| Consensus Rating | None |
|---|
Earnings (AKESF)
| Next Earnings Date | 2026-03-26 |
|---|
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Financials & Fundamentals (AKESF)
| Total Revenue | $3.06B |
|---|---|
| Revenue Growth (YoY) | +49.60% |
| Gross Margin | +77.45% |
| Operating Margin | -30.67% |
| Profit Margin | -36.42% |
| ROE | -14.53% |
| Debt / Equity | 50.93 |
| Current Ratio | 5.14 |
| Total Cash | $9.18B |
| Total Debt | $4.56B |
| Free Cash Flow | $-1.37B |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Financial Health Score (AKESF)
Nexqual rates AKESF's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:56 UTC.
| Growth | Strong — Revenue +44% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 77%, operating -31% |
| Balance Sheet | Strong — $9.18B cash vs $4.56B debt, net cash position |
| Cash Flow | Weak — FCF negative: -$1.37B, burning cash |
| Efficiency | Critical — ROE -15%, ROA -4.3% |
Ownership (AKESF)
| Insider Ownership | +21.64% |
|---|---|
| Institutional Ownership | +31.66% |
| Shares Outstanding | 921.14M |
| Float | 721.82M |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Leadership (AKESF)
AKESF is led by Yu Xia (age 58), Founder, CEO, President & Chairwoman, per Nexqual as of June 9, 2026 at 23:56 UTC.
| Founder, CEO, President & Chairwoman | Yu Xia (age 58) |
|---|---|
| Co-Founder, Executive VP, CSO & Executive Director | Baiyong Li (age 56) |
| Co-Founder, Senior VP & Executive Director | Zhongmin Wang (age 56) |
| Co-Founder, Senior VP & Executive Director | Peng Zhang (age 48) |
| Senior Vice President | Yu Xia (age 54) |
Major Backers & Investors (AKESF)
Notable institutional backers of AKESF include Fidelity, American Century ETF Trust-Avantis Emerging Markets Equity ETF, according to Nexqual as of June 9, 2026 at 23:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.43% |
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.38% |
| BlackRock | 1.13% |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IVBXF | Innovent Biologics Inc. | USD 10.76 | ▲ 6.6% |
| AKBLF | ALK-ABELLO A/S | USD 31.35 | ▼ 19.39% |
| ZLDPF | Zealand Pharma A/S | USD 42.03 | ▼ 15.52% |
| WXXWY | Wuxi Biologics (Cayman) Inc | USD 7.6 | ▼ 7.09% |
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 4.4 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:56 UTC. This page is informational and not investment advice.